Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 5/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239288 | 0.94 | FAAH (0.36) | FAAHMAPTEPHX2L3MBTL1 | |
| SCHEMBL12239243 | 0.88 | BRD4 (0.36) | MAPT | |
| SCHEMBL12239347 | 0.86 | FASN (0.37) | MAPT | |
| SCHEMBL12239350 | 0.85 | ALDH1A1 (0.34) | MAPTPOLB | |
| SCHEMBL12239349 | 0.85 | CXCR3 (0.32) | AOC2MAPTEPHX2TLR9TLR8 | |
| SCHEMBL12239295 | 0.85 | MEN1 (0.39) | MAPTL3MBTL1 | |
| SCHEMBL12239250 | 0.85 | THRB (0.34) | MAPTEPHX2PDE4B | |
| SCHEMBL12239369 | 0.84 | DPP8 (0.33) | DPP8DPP7MAPT | |
| SCHEMBL12239232 | 0.84 | MAPT (0.36) | MAPT | |
| SCHEMBL12239320 | 0.83 | NPC1 (0.38) | EPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313370-B1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA LTD (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-9096560-B2 | 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides | SYNGENTA LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096560-B2 | 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides | SYNGENTA LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010000773-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA LIMITED (GB) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | DDT, CYP1B1, AHR | AOC2 227/4885MAOA 1657/4885DPP8 2127/4885 |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | ACHE, ALG1, KEAP1 | AOC2 694/4885MAOA 767/4885DPP8 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.